Ferroptosis-centered Disease Response Information
General Information of the Disease (ID: DIS00014)
| Name |
Burkitt lymphoma
|
||||
|---|---|---|---|---|---|
| ICD |
ICD-11: 2A85
|
||||
Full List of Target(s) of This Ferroptosis-centered Disease
Glutathione-specific gamma-glutamylcyclotransferase 1 (CHAC1)
| In total 1 item(s) under this target | |||||
| Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | ||||
| Target for Ferroptosis | Marker/Driver | ||||
| Responsed Disease | Burkitt lymphoma [ICD-11: 2A85] | ||||
| Responsed Drug | Artesunate | Investigative | |||
| Responsed Regulator | Cyclic AMP-dependent transcription factor ATF-4 (ATF4) | Driver | |||
| Pathway Response | Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | ||||
| Cell proliferation | |||||
| In Vitro Model | Daudi cells | Burkitt lymphoma | Homo sapiens | CVCL_0008 | |
| CA46 cells | Burkitt lymphoma | Homo sapiens | CVCL_1101 | ||
| In Vivo Model |
Four -week-old NOD/SCID mice were purchased from Chu Shang Technology (Kunming, China). CA-46 cells were collected and re-suspended in PBS at a concentration of 1-5 x 107 cells/mL. Totally, 0.2 mL cells were inoculated subcutaneously in the middle and posterior armpits of mice. When the transplanted tumor was established, the mice were injected the artesunate solution intraperitoneally in accordance with the body weight (200 mg/kg) daily.
Click to Show/Hide
|
||||
| Response regulation | Artesunate induced ferroptosis in different types of Burkitt's lymphoma cells, and caused a significant ERS response in tumor cells. The activation of the ATF4-CHOP-CHAC1 pathway up-regulated the expression of CHAC1 and degraded intracellular GSH, thus weakening the ability of lymphoma cells to resist ferroptosis. | ||||